Intelligent Bio Solutions closes $10M private placement; funds FDA submission and expansion

Each Series K-1 Warrant and Series K-2 Warrant is exercisable into one share of Common Stock at a price per share of $4.10 (as adjusted from time to time in accordance with the terms thereof).

The combined purchase price of one share of Common Stock (or one Pre-Funded Warrant) and accompanying Series K-1 Warrant and Series K-2 Warrant was $4.35. The Offering closed on January 2, 2026. At the closing of the Offering, 105,000 Shares were issued and 2,193,850 Pre-Funded Warrants were issued.

On December 31, 2025, Intelligent Bio Solutions Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two healthcare focused institutional investors for the sale by the Company of (i) 2,298,850 shares (the “Shares”) of the Company’s common stock (or Series L Pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”)), par value $0.01 per share (the “Common Stock”), (ii) Series K-1 warrants to purchase up to an aggregate of 2,298,850 shares of Common Stock (the “Series K-1 Warrants”), and (iii) Series K-2 warrants to purchase up to an aggregate of 2,298,850 shares of Common Stock (the “Series K-2 Warrants” and, collectively with the Series K-1 Warrants and Pre-Funded Warrants, the “Warrants”), in a private placement offering (the “Offering”).